NCT07240909Not yet recruitingPhase 4
Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
A Multicenter, Randomized, PROBE Trial on Antihypertensive Drug Selection Based on Hemodynamic Phenotypes Defined by Bioelectrical Impedance Analysis
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
The goal of this clinical trial is to explore the clinical efficacy and safety of individualized antihypertensive medication guided by hemodynamic phenotyping. The main questions it aims to answer are: 1. Does hemodynamics-based individualized antihypertensive therapy achieve better blood pressure control compared to guideline-based conventional therapy? 2. Does hemodynamics-based individualized therapy have comparable safety to guideline-based conventional treatment? Researchers will compare hemodynamics-based individualized antihypertensive therapy to guideline-based conventional treatment to see if the former is better than the latter. Participants will: 1. Take hemodynamics-based individualized antihypertensive therapy or guideline-based conventional treatment every day for 8 weeks 2. Visit the clinic once every 4 weeks for checkups and tests 3. Keep a diary of their symptoms and any treatment
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 13 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The Third Xiangya Hospital of Central South University
- Diseases
- High blood pressure
- NCT number
- NCT07240909
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 240
- From 1 Jan 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent or planned use of medications contraindicated or requiring caution with trial drugs;
- Concurrent or planned use of medications interfering with trial outcomes;
Other illness
- Diagnosed or highly suspected secondary hypertension;
- Allergy to the intended antihypertensive medications;
- Comorbid conditions leading to inaccurate blood pressure measurement;
- Comorbid conditions or states unsuitable for noninvasive hemodynamic measurement via bioelectrical impedance;
- Comorbid conditions contraindicating or requiring caution with trial medications;
- Comorbid conditions affecting the absorption, distribution, metabolism, or excretion of trial drugs;
Other
- Classified as mixed type according to hemodynamic typing;
- Dysphagia;
- Pregnant or lactating women;
- Potential pregnancy plans during the trial period;
- Uncorrected electrolyte disturbances;
- Severe organ dysfunction;
- Clinician's assessment deems the patient unsuitable for the trial's antihypertensive regimen;
- Current participation in other clinical studies that may interfere with the conduct of this trial.
Who the study is looking for
- Aged ≥30 and \<80 years, regardless of gender;
- Confirmed diagnosis of hypertension meeting the criteria outlined in the 2024 Chinese Hypertension Guidelines: office blood pressure ≥140/90 mmHg and home blood pressure ≥135/85 mmHg;
- Mild to moderate hypertension, with office blood pressure ranging from 140-179/90-109 mmHg;
- No prior use of antihypertensive medications;
- Voluntary participation in the study with written informed consent obtained.
Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.